RELMADA THERAPEUTICS, INC. (RLMD) has 74 open-market insider trades by 8 insiders since 2015. Over the last six months insiders net bought $1.7M. The most active filer is Sergio Traversa, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Sergio Traversa | CEO | — | 18 | $6.5M | 2026-09-10 |
| Maged Shenouda | CFO | — | 16 | $3.5M | 2026-09-10 |
| Paul Edward Kelly | COO | — | 15 | $2.0M | 2025-11-05 |
| Charles J. Casamento | Dir | — | 17 | $1.5M | 2024-10-22 |
| Chuck Ence | COOCAO | — | 3 | $712K | 2025-11-05 |
| Sandesh Seth | Dir | — | 2 | $61K | 2015-12-15 |
| Cedric O'Gorman | Chief Medical Officer | — | 1 | $32K | 2023-05-23 |
| Shreeram Agharkar | Dir | — | 2 | $5K | 2015-12-31 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Sergio Traversa | CEO | Buy | $828K | 2026-09-09 |
| Maged Shenouda | CFO | Buy | $844K | 2026-09-09 |
| Maged Shenouda | CFO | Buy | $48K | 2025-12-15 |
| Sergio Traversa | CEO | Buy | $113K | 2025-12-15 |
| Maged Shenouda | CFO | Buy | $1.1M | 2025-11-05 |
| Paul Edward Kelly | COO | Buy | $396K | 2025-11-05 |
Companies that share insiders with RLMD, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Sergio Traversa | CEO | Buy | $600K | 2025-11-05 |
| Chuck Ence | COO & CAO | Buy | $299K | 2025-11-05 |
| Sergio Traversa | CEO | Buy | $265K | 2025-08-26 |
| Paul Edward Kelly | COO | Buy | $86K | 2025-05-16 |
| Sergio Traversa | CEO | Buy | $335K | 2025-05-16 |
| Chuck Ence | — | Buy | $206K | 2025-05-16 |
| Maged Shenouda | CFO | Buy | $97K | 2025-05-16 |
| Maged Shenouda | CFO | Buy | $207K | 2024-09-09 |
| Sergio Traversa | CEO | Buy | $790K | 2024-09-09 |